

# PJ34

Catalog No: tcsc1463



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

344458-19-1

**Formula:**

$C_{17}H_{17}N_3O_2$

**Pathway:**

Epigenetics;Cell Cycle/DNA Damage

**Target:**

PARP;PARP

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 30 mg/mL (101.58 mM; Need ultrasonic and warming)

**Observed Molecular Weight:**

295.34

## Product Description


PJ34 is a potent specific inhibitor of **PARP1/2** with **IC<sub>50</sub>** of 110 nM and 86 nM, respectively.

IC50 & Target: IC50: 110 nM (PARP1), 86 nM (PARP2)<sup>[1]</sup>

***In Vitro:***

PJ34 inhibits the PARP enzyme activity with an  $IC_{50}$  of  $110 \pm 1.9$  nM. To compare the neuroprotective properties of other PARP inhibitors in PC12 cells, PJ34 is evaluated using by LDH assay. PJ34 treatment also significantly and concentration dependently attenuates cell death at a concentration ranging from  $10^{-7}$  to  $10^{-5}$  M<sup>[1]</sup>.

***In Vivo:*** To compare the potency and efficacy with other PARP inhibitors, PJ34 is evaluated at the doses of 3.2 and 10 mg/kg, respectively. PJ34 at the dose of 3.2 mg/kg significantly reduces cortical damage by 33%; however, 10 mg/kg dosing shows reversed effect (17% reduction)<sup>[1]</sup>. PJ34 (25 mg/kg) reduces the levels of TNF- $\alpha$  mRNA in ischemic animals by 70% and these values in treated mice do not differ from that of sham or naive animals. Treatment of ischemic mice with PJ34 reduces the level of E-selectin mRNA by 81% and that of ICAM-1 mRNA by 54%, compared to vehicle-treated ischemic mice<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!